Inovio Pharmaceuticals, Inc stock page - price, fundamentals, dividends - iOCharts

INO

6.79
-0.05 (-0.73%)
Inovio Pharmaceuticals, Inc (NASDAQ, USD)
Healthcare >
Biotechnology
Market cap
1.42B
Ent value
1.41B
Price/Sales
191.85
Price/Book
2.44
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
-
Forward P/E
-
PEG
-
EPS growth
-14.60%
1 year return
-38.88%
3 year return
10.67%
5 year return
-0.09%
10 year return
11.16%
Last updated: 2021-10-27

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open6.90
Daily high6.98
Daily low6.77
Daily Volume2.04M
All-time high191.00
1y analyst estimate14.00
Beta0.65
EPS (TTM)-0.89
Dividend per share-
Ex-div date28 Sep 2017
Next earnings date8 Nov 2021

Downside potential

Loading...
Downside potential data
INOS&P500
Current price drop from All-time high-96.44%-0.44%
Highest price drop-99.66%-56.47%
Date of highest drop19 Nov 20089 Mar 2009
Avg drop from high-90.95%-11.44%
Avg time to new high384 days12 days
Max time to new high5445 days1805 days

DIVIDENDS

INO does not pay dividends

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E-
Price to OCF-
Price to FCF-
Price to EBITDA-
EV to EBITDA-

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales191.85
Price to Book2.44
EV to Sales190.45

FINANCIALS

Per share

Loading...
Per share data
Current share count209.40M
EPS (TTM)-0.89
FCF per share (TTM)-0.96

Income statement

Loading...
Income statement data
Revenue (TTM)7.41M
Gross profit (TTM)7.41M
Operating income (TTM)-124.08M
Net income (TTM)-166.41M
EPS (TTM)-0.89
EPS (1y forward)-0.25

Margins

Loading...
Margins data
Gross margin (TTM)100.00%
Operating margin (TTM)-1674.25%
Profit margin (TTM)-2245.39%

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash83.63M
Net receivables10.26M
Total current assets588.43M
Goodwill10.51M
Intangible assets3.01M
Property, plant and equipment23.39M
Total assets654.86M
Accounts payable26.74M
Short/Current long term debt33.90M
Total current liabilities41.54M
Total liabilities73.26M
Shareholder's equity581.61M
Net tangible assets568.08M

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)-177.98M
Capital expenditures (TTM)1.52M
Free cash flow (TTM)-179.50M
Dividends paid (TTM)0.00

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity-36.09%
Return on Assets-30.83%
Return on Invested Capital-34.68%
Cash Return on Invested Capital-37.41%
COMPANY DETAILS
INO (Inovio Pharmaceuticals, Inc) company logo
Marketcap
1.42B
Marketcap category
Small-cap
Description
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon optimized plasmids that have ability to help break the immune system's tolerance of cancerous or infected cells and facilitate cross-strain protection against unmatched and matched pathogen variants. The company is involved in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, including head and neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, such as recurrent respiratory papillomatosis; glioblastoma multiforme; prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); Lassa fever; Zika virus; and the COVID-19 virus (coronavirus). Its partners and collaborators include ApolloBio Corp., AstraZeneca, Beijing Advaccine Biotechnology Co., Ltd., The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron, Thermo Fisher Scientific, University of Pennsylvania, Walter Reed Army Institute of Research, and The Wistar Institute. The company also has an agreement with Richter-Helm BioLogics GmbH & Co. KG to support investigational DNA vaccine INO-4800, which is currently in Phase I clinical testing for COVID-19; and a partnership with International Vaccine Institute and Seoul National University Hospital. The company was founded in 1979 and is headquart
Employees
262
Investor relations
SEC filings
CEO
Jong Kim
Country
USA
City
San Diego
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
INOVIO (NASDAQ: INO) announced today that third quarter 2021 financial results will be released after the market close on November 9, 2021. Following the release, INOVIO will host a live conference ca...
October 27, 2021
Is INO stock a buy after Brazil, the Philippines and Mexico gave it the go-ahead to run Covid vaccine testing? Is Inovio stock a buy now?
October 26, 2021
INOVIO (NASDAQ: INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, ...
October 26, 2021
INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, t...
October 21, 2021
Inovio Pharmaceuticals, Inc. ( NASDAQ:INO ) is possibly approaching a major achievement in its business, so we would...
October 20, 2021
Based on analysts' loftiest price targets, these companies could nearly triple or potentially quintuple investors' money over the next year.
October 13, 2021
INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, t...
October 12, 2021
INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, t...
October 11, 2021
It seems such a long time ago that Inovio Pharmaceuticals (NASDAQ: INO) was considered one of the leaders in the hunt for a COVID-19 vaccine -- but the biotech was left in the dust by peers and many i...
October 6, 2021
INOVIO (NASDAQ:INO), a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated dis...
September 29, 2021
Next page